We are a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs. Our principal office in Asia provides easy access to prosperous medical research resources and some of the worldâs most talented specialists and clinicians. We have established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations. To date, Aptorum has obtained 12 exclusively licensed technologies in the areas of neurology, infectious diseases, gastroenterology, oncology, surgical robotics and natural health. Source
No articles found.
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Medpace is a scientifically-driven, global, full-service clinical contract researc...
Medpace is a scientifically-driven, global, ful...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Join the National Investor Network and get the latest information with your interests in mind.